Analytical Data
-
基因名
E7
- Application
-
别名
E7；SIAT7E；Alpha-N-acetylgalactosaminide alpha-2.6-sialyltransferase 5
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9BVH7
-
表达区间
1-336aa
-
氨基酸序列
MKTLMRHGLAVCLALTTMCTSLLLVYSSLGGQKERPPQQQQQQQQQQQQASATGSSQPAAESSTQQRPGVPAGPRPLDGYLGVADHKPLKMHCRDCALVTSSGHLLHSRQGSQIDQTECVIRMNDAPTRGYGRDVGNRTSLRVIAHSSIQRILRNRHDLLNVSQGTVFIFWGPSSYMRRDGKGQVYNNLHLLSQVLPRLKAFMITRHKMLQFDELFKQETGKDRKISNTWLSTGWFTMTIALELCDRINVYGMVPPDFCRDPNHPSVPYHYYEPFGPDECTMYLSHERGRKGSHHRFITEKRVFKNWARTFNIHFFQPDWKPESLAINHPENKPVF
-
分子量
38.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
E7 recombinant protein is derived from the oncogenic human papillomavirus (HPV) type 16, which has been implicated in the development of cervical cancer. Research on the E7 protein has gained significant attention due to its critical role in the disruption of cellular regulatory mechanisms, particularly its ability to interact with tumor suppressor proteins such as pRB (retinoblastoma protein). This interaction leads to uncontrolled cell proliferation and contributes to the malignant transformation of host cells. The study of E7 has been pivotal in understanding HPV's oncogenic processes and has facilitated the development of potential therapeutic strategies, including vaccines and immunotherapies aimed at inducing an immune response against HPV-related cancers. Given that HPV infection is a major etiological factor in cervical cancer and other anogenital malignancies, the characterization of E7 and its mechanisms provides crucial insights into preventing and treating these diseases. Furthermore, the recombinant production of E7 allows for its use in experimental settings, enabling researchers to explore its immunogenic properties and assess its potential in clinical applications. The ongoing exploration of E7 recombinant protein continues to be significant for advancing cancer biology and improving patient outcomes in HPV-associated cancers.
